Embolic Protection with the TriGuard 3 System in Nonagenarian Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis.
TAVR
embolic protection
interventional devices
nonagenarians
percutaneous valve therapy
stroke
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Apr 2022
02 Apr 2022
Historique:
received:
28
02
2022
revised:
21
03
2022
accepted:
28
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Transcatheter aortic valve replacement (TAVR) improves the survival and life quality of nonagenarian patients with aortic stenosis. Stroke remains one of the most worrisome complications following TAVR. Cerebral embolic protection devices (CEPDs) may reduce neurological complications after TAVR. This study evaluated the safety and efficacy of CEPDs during TAVR in nonagenarian patients. Between January 2018 and October 2021, 869 patients underwent transfemoral TAVR (TF-TAVR) at our center. Of these, 51 (5.9%) patients were older than ninety years. In 33 consecutive nonagenarian patients, TF-TAVR was implanted without CEPDs using balloon-expandable valves (BEVs) and self-expandable valves (SEVs). Eighteen consecutive nonagenarians underwent TF-TAVR using a CEPD (CP group). Follow up period was in-hospital or 30 days after the procedure, respectively. Minor access site complications occurred in two patients (3.9%) and were not CEPD-associated. Postinterventional delirium occurred in nine patients (17.6%). Periprocedural minor non-disabling stroke and delirium occurred in ten patients (19.6%). Periprocedural major fatal stroke occurred in two patients in the BEV group (3.9%). Two patients in the BEV group died due to postinterventional pneumonia with sepsis. The mortality rate was 7.8%. The results did not differ between the groups. Age alone is no longer a contraindication for TAVR. CEPD using the Triguard 3 system in nonagenarian TAVR patients was feasible and safe and did not increase access site complications.
Sections du résumé
BACKGROUND
BACKGROUND
Transcatheter aortic valve replacement (TAVR) improves the survival and life quality of nonagenarian patients with aortic stenosis. Stroke remains one of the most worrisome complications following TAVR. Cerebral embolic protection devices (CEPDs) may reduce neurological complications after TAVR. This study evaluated the safety and efficacy of CEPDs during TAVR in nonagenarian patients.
METHODS
METHODS
Between January 2018 and October 2021, 869 patients underwent transfemoral TAVR (TF-TAVR) at our center. Of these, 51 (5.9%) patients were older than ninety years. In 33 consecutive nonagenarian patients, TF-TAVR was implanted without CEPDs using balloon-expandable valves (BEVs) and self-expandable valves (SEVs). Eighteen consecutive nonagenarians underwent TF-TAVR using a CEPD (CP group). Follow up period was in-hospital or 30 days after the procedure, respectively.
RESULTS
RESULTS
Minor access site complications occurred in two patients (3.9%) and were not CEPD-associated. Postinterventional delirium occurred in nine patients (17.6%). Periprocedural minor non-disabling stroke and delirium occurred in ten patients (19.6%). Periprocedural major fatal stroke occurred in two patients in the BEV group (3.9%). Two patients in the BEV group died due to postinterventional pneumonia with sepsis. The mortality rate was 7.8%. The results did not differ between the groups.
CONCLUSIONS
CONCLUSIONS
Age alone is no longer a contraindication for TAVR. CEPD using the Triguard 3 system in nonagenarian TAVR patients was feasible and safe and did not increase access site complications.
Identifiants
pubmed: 35407611
pii: jcm11072003
doi: 10.3390/jcm11072003
pmc: PMC8999484
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Interv Cardiol. 2018 Oct;31(5):648-654
pubmed: 29900591
J Gen Intern Med. 2011 Jul;26(7):783-90
pubmed: 21286840
EuroIntervention. 2015 May;11(1):75-84
pubmed: 25868876
J Am Coll Cardiol. 2017 Jan 31;69(4):367-377
pubmed: 27815101
JACC Cardiovasc Interv. 2021 Mar 8;14(5):515-527
pubmed: 33663779
JACC Cardiovasc Interv. 2010 Nov;3(11):1126-32
pubmed: 21087747
EuroIntervention. 2012 May 15;8(1):129-38
pubmed: 22391581
Catheter Cardiovasc Interv. 2017 Feb 15;89(3):470-477
pubmed: 27121306
Eur Heart J. 2021 Mar 7;42(10):963-964
pubmed: 33316042
Eur Heart J. 2015 Aug 14;36(31):2070-2078
pubmed: 25990342
Eur Heart J. 2019 May 1;40(17):1340-1341
pubmed: 30602014
JACC Cardiovasc Interv. 2016 Jan 25;9(2):171-9
pubmed: 26723763
JACC Cardiovasc Interv. 2017 Nov 27;10(22):2297-2303
pubmed: 28917515
Eur Heart J Cardiovasc Imaging. 2017 Mar 1;18(3):254-275
pubmed: 28363204
Cardiovasc Interv Ther. 2021 Nov 13;:
pubmed: 34773568
Clin Res Cardiol. 2015 May;104(5):430-8
pubmed: 25596724
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Ann Thorac Surg. 2014 Jan;97(1):29-36
pubmed: 24140210
Disabil Rehabil. 2017 Jul;39(14):1435-1440
pubmed: 27385479
EuroIntervention. 2016 Jul 20;12(4):499-507
pubmed: 27436602
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Int J Cardiol. 2015 Sep 15;195:216-24
pubmed: 26048380
J Am Coll Cardiol. 2021 Mar 9;77(9):1149-1161
pubmed: 33663731
J Geriatr Cardiol. 2018 Feb;15(2):123-130
pubmed: 29662505
Circulation. 2012 Sep 4;126(10):1245-55
pubmed: 22899774
Eur Heart J. 2012 Oct;33(19):2403-18
pubmed: 23026477
Am J Cardiol. 2021 May 1;146:69-73
pubmed: 33556360
J Am Coll Cardiol. 2016 Mar 29;67(12):1387-1395
pubmed: 27012397
Eur Stroke J. 2019 Dec;4(4):307-317
pubmed: 31903429
JACC Cardiovasc Interv. 2019 May 27;12(10):911-920
pubmed: 31122347
JACC Cardiovasc Interv. 2019 Mar 11;12(5):459-469
pubmed: 30846085
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
J Am Heart Assoc. 2019 Apr 2;8(7):e011504
pubmed: 30897991
Eur Heart J. 2019 May 1;40(17):1334-1340
pubmed: 30590554
Eur Heart J. 2021 May 14;42(19):1825-1857
pubmed: 33871579
J Community Hosp Intern Med Perspect. 2021 Jan 26;11(1):128-134
pubmed: 33552435
Ann Transl Med. 2019 Oct;7(20):584
pubmed: 31807565
JAMA. 2016 Aug 9;316(6):592-601
pubmed: 27532914
Cardiovasc Revasc Med. 2018 Oct;19(7 Pt A):785-791
pubmed: 29550047
Ann Thorac Surg. 2021 May;111(5):1520-1528
pubmed: 32980326
JACC Cardiovasc Interv. 2021 Jan 25;14(2):161-168
pubmed: 33478631
JACC Cardiovasc Interv. 2016 Oct 24;9(20):2124-2133
pubmed: 27765306
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Stroke. 2018 Mar;49(3):796-802
pubmed: 29371430
EuroIntervention. 2019 Jun 20;15(2):147-154
pubmed: 30777842
EuroIntervention. 2020 Aug 07;16(6):e507-e509
pubmed: 32091398
J Interv Cardiol. 2018 Dec;31(6):891-898
pubmed: 30467892
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
J Cardiol. 2021 Jul;78(1):44-50
pubmed: 33563507